Eagle Global Advisors LLC reduced its stake in Enzo Biochem, Inc. (NYSE:ENZ) by 34.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 73,200 shares of the medical research company’s stock after selling 39,000 shares during the period. Eagle Global Advisors LLC owned about 0.16% of Enzo Biochem worth $808,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. American International Group Inc. raised its position in Enzo Biochem by 7.1% in the first quarter. American International Group Inc. now owns 24,432 shares of the medical research company’s stock valued at $204,000 after buying an additional 1,610 shares during the period. Bank of New York Mellon Corp raised its position in Enzo Biochem by 1.2% in the first quarter. Bank of New York Mellon Corp now owns 206,447 shares of the medical research company’s stock valued at $1,728,000 after buying an additional 2,409 shares during the period. Campbell & CO Investment Adviser LLC raised its position in Enzo Biochem by 24.4% in the first quarter. Campbell & CO Investment Adviser LLC now owns 14,325 shares of the medical research company’s stock valued at $120,000 after buying an additional 2,812 shares during the period. Gilder Gagnon Howe & Co. LLC raised its position in Enzo Biochem by 0.9% in the first quarter. Gilder Gagnon Howe & Co. LLC now owns 831,354 shares of the medical research company’s stock valued at $6,958,000 after buying an additional 7,401 shares during the period. Finally, Berson & Corrado Investment Advisors LLC raised its position in Enzo Biochem by 3.9% in the second quarter. Berson & Corrado Investment Advisors LLC now owns 326,101 shares of the medical research company’s stock valued at $3,600,000 after buying an additional 12,190 shares during the period. Hedge funds and other institutional investors own 61.27% of the company’s stock.
Enzo Biochem, Inc. (NYSE ENZ) opened at 11.08 on Thursday. The firm has a market cap of $514.19 million, a price-to-earnings ratio of 15.54 and a beta of 0.97. The firm has a 50-day moving average of $11.16 and a 200 day moving average of $8.74. Enzo Biochem, Inc. has a 52-week low of $4.88 and a 52-week high of $12.04.
TRADEMARK VIOLATION NOTICE: This article was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://stocknewstimes.com/2017/08/03/eagle-global-advisors-llc-sells-39000-shares-of-enzo-biochem-inc-enz.html.
Several research firms have issued reports on ENZ. BidaskClub upgraded shares of Enzo Biochem from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 19th. Zacks Investment Research upgraded shares of Enzo Biochem from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Tuesday, June 20th.
Enzo Biochem Company Profile
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem, Inc. (NYSE:ENZ).
Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
